Recent Development in Clinical Applications of PD-1 and PD-L1 Antibodies for Cancer Immunotherapy

Authors

B Liu
Y Song
Delong Liu, New York Medical CollegeFollow

DOI

10.1186/s13045-017-0541-9

Journal Title

Journal of Hematology & Oncology

First Page

174

Document Type

Article

Publication Date

12-1-2017

Department

Medicine

Keywords

pemetrexed, pembrolizumab, non small-cell lung carcinoma, carboplatin, lung neoplasms, human CD274 protein, B7-H1 antigen, humanized monoclonal antibodies, protein tyrosine kinases

Disciplines

Medicine and Health Sciences

Abstract

Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy.

Recommended Citation

Liu, B., Song, Y., & Liu, D. (2017). Recent Development in Clinical Applications of PD-1 and PD-L1 Antibodies for Cancer Immunotherapy. Journal of Hematology & Oncology, 10 (1), 174. https://doi.org/10.1186/s13045-017-0541-9

Publisher's Statement

Originally published in Journal of Hematology & Oncology 2017 10:174. The original material can be found here.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.